fashion -WSS

fashion

author：fashion 2025-10-01 21:34:59 - browse：3

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Medicare Advantage plans can’t deny care with AI, CMS warns

WSS

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Violet CEO on training clinicians to promote more inclusive care

Why CTE doesn’t keep Americans from enjoying the Super Bowl

SEC charges former device maker CEO with $41 million fraud

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Johnson & Johnson sued for allegedly overpaying for workers' drugs

entertainment

fashion

focus

Medicare details structure of new drug price negotiation program

Updated Covid vaccine has 54% effectiveness, new study suggests

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD: Venture capital, Gilead, and more M&A

Trump demands the U.S. pay no more for drugs than other countries … again

AstraZeneca stays mum on Medicare drug pricing negotiations

Activists slam private health insurers over coverage restrictions

CRISPR gene editing developments we’re watching in 2024

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: The latest on Moderna, Apellis, and Merck

knowledge

David Ricks of Eli Lilly: best biopharma CEO of 2023

Adopting new red light myopia treatments may be short

CRISPR gene editing developments we’re watching in 2024

CRISPR gene editing developments we’re watching in 2024

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Readout LOUD: Venture capital, Gilead, and more M&A

explore

leisure time

knowledge

focus